Watson Pharmaceuticals has received FDA approval for a generic version of Duramed Pharmaceuticals’ Plan B (levonorgestrel tablets) for postpubertal women ≤17 years old.
This product is indicated for the prevention of pregnancy after known or suspected contraceptive failure or unprotected intercourse.
Watson intends to market the product under the trade name Next Choice. It will be available by prescription only.
For more information call (800) 272-5525 or visit www.watson.com.
Related Content